- See our top-yielding stocks list.
- See our dividend calendar.
Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.
In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.
Following Thursday's closing bell, PDL BioPharma (PDLI) reported lower-than-expected revenue for the 2016 second quarter.
Trade-Ideas LLC identified PDL BioPharma (PDLI) as a weak on high relative volume candidate